2026 Global: Artificial Cardiac Valves Market -Competitive Review (2032) report
Description
The 2026 Global: Artificial Cardiac Valves Market-Competitive Review (2032) report features the global market size and projected growth/decline data for the period 2021 and 2032. The report primarily provides an examination of the business strategies for the ten largest global companies in the market and how their strategies differ.
Edwards Lifesciences Corporation, headquartered in Irvine, California, United States, is a global leader in structural heart devices, with the SAPIEN transcatheter heart valve family contributing heavily to the modern TAVR market. Medtronic plc, based in Dublin, Ireland, remains a dominant force with Evolut and CoreValve platforms, extensive clinical programs, and a broad valve portfolio spanning surgical and transcatheter therapy. Abbott Laboratories, headquartered in Abbott Park, Illinois, United States, markets the Portico transcatheter heart valve alongside deep surgical-valve offerings and post-implant care. Boston Scientific Corporation, based in Marlborough, Massachusetts, United States, commands a significant share with Lotus Edge and related transcatheter systems, while LivaNova plc, headquartered in London, United Kingdom, contributes with Perceval’s sutureless aortic-valve technology and complementary cardiac devices. Collectively, these five firms set the pace in artificial cardiac valves, driving regulatory approvals, clinical adoption, and expanding indications across diverse patient populations. Their pipelines integrate surgical, transcatheter, and hybrid approaches.
CryoLife, Inc., headquartered in Kennesaw, Georgia, United States, concentrates on prosthetic and tissue-heart valves, including cryopreserved human valves, and pursues complementary transcatheter therapies through partnerships and research initiatives. Meril Life Sciences Pvt. Ltd., headquartered in Mumbai, India, is a growing cardiovascular-device company delivering surgical valves, transcatheter valve systems, and related support equipment, with expanding distribution across Asia, Europe, and the Americas. MicroPort Scientific Corporation, headquartered in Shanghai, China, is a diversified cardiovascular device company active in transcatheter heart valves, surgical valves, and interventional devices, with a rapidly expanding global footprint. Venus MedTech Co., Ltd., headquartered in Beijing, China, markets the Venus A-Valve and associated structural-heart products, advancing clinical adoption through multicenter trials and international collaborations. JenaValve Technology GmbH, headquartered in Jena, Germany, focuses on repositionable transcatheter valve solutions, pursuing early access programs and multi-center registries to validate complex anatomies. Together these firms complement surgical capabilities with less invasive therapy options.
These ten companies together shape the trajectory of the artificial cardiac valves market by advancing device miniaturization, expanding indications, and refining delivery systems to broaden patient access. Across North America, Europe, and Asia, their competing portfolios—ranging from durable surgical bioprostheses to next-generation transcatheter valves and hybrid therapies—drive ongoing clinical trials, postmarket surveillance, and evidence-based adoption. Regulatory collaborations, physician education, and incremental improvements in device profiles, such as repositionable or sutureless designs, influence procedural choice and patient eligibility. While Edwards Lifesciences and Medtronic lead with scale and global reach, others such as Meril Life Sciences, MicroPort, Venus MedTech, and JenaValve exploit regional opportunities to address unmet needs and price dynamics. CryoLife’s tissue-based offerings provide alternatives for surgeons prioritizing biological compatibility, while Abbott, Boston Scientific, and LivaNova push value-based models through integrated care pathways. The resulting competition accelerates innovation, expands access, and reshapes the landscape of modern valvular care worldwide.
Edwards Lifesciences Corporation, headquartered in Irvine, California, United States, is a global leader in structural heart devices, with the SAPIEN transcatheter heart valve family contributing heavily to the modern TAVR market. Medtronic plc, based in Dublin, Ireland, remains a dominant force with Evolut and CoreValve platforms, extensive clinical programs, and a broad valve portfolio spanning surgical and transcatheter therapy. Abbott Laboratories, headquartered in Abbott Park, Illinois, United States, markets the Portico transcatheter heart valve alongside deep surgical-valve offerings and post-implant care. Boston Scientific Corporation, based in Marlborough, Massachusetts, United States, commands a significant share with Lotus Edge and related transcatheter systems, while LivaNova plc, headquartered in London, United Kingdom, contributes with Perceval’s sutureless aortic-valve technology and complementary cardiac devices. Collectively, these five firms set the pace in artificial cardiac valves, driving regulatory approvals, clinical adoption, and expanding indications across diverse patient populations. Their pipelines integrate surgical, transcatheter, and hybrid approaches.
CryoLife, Inc., headquartered in Kennesaw, Georgia, United States, concentrates on prosthetic and tissue-heart valves, including cryopreserved human valves, and pursues complementary transcatheter therapies through partnerships and research initiatives. Meril Life Sciences Pvt. Ltd., headquartered in Mumbai, India, is a growing cardiovascular-device company delivering surgical valves, transcatheter valve systems, and related support equipment, with expanding distribution across Asia, Europe, and the Americas. MicroPort Scientific Corporation, headquartered in Shanghai, China, is a diversified cardiovascular device company active in transcatheter heart valves, surgical valves, and interventional devices, with a rapidly expanding global footprint. Venus MedTech Co., Ltd., headquartered in Beijing, China, markets the Venus A-Valve and associated structural-heart products, advancing clinical adoption through multicenter trials and international collaborations. JenaValve Technology GmbH, headquartered in Jena, Germany, focuses on repositionable transcatheter valve solutions, pursuing early access programs and multi-center registries to validate complex anatomies. Together these firms complement surgical capabilities with less invasive therapy options.
These ten companies together shape the trajectory of the artificial cardiac valves market by advancing device miniaturization, expanding indications, and refining delivery systems to broaden patient access. Across North America, Europe, and Asia, their competing portfolios—ranging from durable surgical bioprostheses to next-generation transcatheter valves and hybrid therapies—drive ongoing clinical trials, postmarket surveillance, and evidence-based adoption. Regulatory collaborations, physician education, and incremental improvements in device profiles, such as repositionable or sutureless designs, influence procedural choice and patient eligibility. While Edwards Lifesciences and Medtronic lead with scale and global reach, others such as Meril Life Sciences, MicroPort, Venus MedTech, and JenaValve exploit regional opportunities to address unmet needs and price dynamics. CryoLife’s tissue-based offerings provide alternatives for surgeons prioritizing biological compatibility, while Abbott, Boston Scientific, and LivaNova push value-based models through integrated care pathways. The resulting competition accelerates innovation, expands access, and reshapes the landscape of modern valvular care worldwide.
Table of Contents
32 Pages
- 1.0 Scope of Report and Methodology
- 2.0 Market SWOT Analysis and Players
- 2.1 Market Definition
- 2.2 Market Segments
- 2.3 Market Strengths
- 2.4 Market Weaknesses
- 2.5 Market Threats
- 2.6 Market Opportunities
- 2.7 Major Players
- 3.0 Competitive Analysis
- 3.1 Market Player 1
- 3.2 Market Player 2
- 3.3 Market Player 3
- 3.4 Market Player 4
- 3.5 Market Player 5
- 3.6 Market Player 6
- 3.7 Market Player 7
- 3.8 Market Player 8
- 3.9 Market Player 9
- 3.10 Market Player 10
- 4.0 Comparative Business Strategies
- 4.1 Comparative Business Strategies of Player 1 and 2
- 4.2 Comparative Business Strategies of Player 1 and 3
- 4.3 Comparative Business Strategies of Player 1 and 4
- 4.4 Comparative Business Strategies of Player 2 and 3
- 4.5 Comparative Business Strategies of Player 2 and 4
- 4.6 Comparative Business Strategies of Player 3 and 4
- 5.0 Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
